Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE

(GSK)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
04/12/2019 04/15/2019 04/16/2019 04/17/2019 04/18/2019 Date
1551.2(c) 1550(c) 1554.8(c) 1540.8(c) 1524.4(c) Last
8 819 959 6 392 979 5 180 981 7 429 522 5 908 269 Volume
-0.92% -0.08% +0.31% -0.90% -1.06% Change
More quotes
Financials (GBP)
Sales 2019 31 811 M
EBIT 2019 8 416 M
Net income 2019 4 134 M
Debt 2019 24 199 M
Yield 2019 5,25%
Sales 2020 34 025 M
EBIT 2020 8 991 M
Net income 2020 4 561 M
Debt 2020 22 355 M
Yield 2020 5,25%
P/E ratio 2019 16,99
P/E ratio 2020 16,59
EV / Sales2019 3,15x
EV / Sales2020 2,89x
Capitalization 76 032 M
More Financials
Company
GlaxoSmithkline is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (56%): intended for respiratory diseases (40.1% of net sales), HIV infection (27.3%), immune system disorders (2.7%) ) and other (29,8%); - OTC and... 
Sector
Pharmaceuticals
Calendar
05/01 | 07:00amEarnings Release
More about the company
Surperformance© ratings of GlaxoSmithKline
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE
04/18GLAXOSMITHKLINE : QuantuMDx Group Ltd has announced plans to expand the potentia..
AQ
04/18LONDON STOCK EXCHANGE : FTSE 100 dips on sluggish euro zone PMI, Unilever sparkl..
RE
04/18GLAXOSMITHKLINE : QuantuMDx Group Ltd has announced plans to expand the potentia..
AQ
04/17London's shares off six-month highs, Bunzl suffers worst day in a decade
RE
04/15LONDON STOCK EXCHANGE : London's FTSE 100 subdued, IWG lifts midcaps
RE
04/15LONDON STOCK EXCHANGE : London's FTSE 100 tugged down by miners; IWG lifts midca..
RE
04/09GLAXOSMITHKLINE : FDA approves ViiV's two-drug HIV regimen, Dovato
PU
04/08GSK wins U.S. nod for two-drug HIV combination
RE
04/08FDA Approves Two-Drug Combination HIV Treatment
DJ
04/04U.S., China key to GSK's consumer venture with Pfizer
RE
More news
Analyst Recommendations on GLAXOSMITHKLINE
More recommendations
Sector news : Pharmaceuticals - NEC
04/19TEVA PHARMACEUTICAL INDUSTRIES : Pharma Gets FDA Approval to Market Generic Nasa..
DJ
04/18Pfizer, Lilly Release Top-Line Results From Phase 3 Study of Tanezumab for Os..
DJ
04/18Pfizer, Johnson & Johnson Weigh on Pharmaceutical ETFs
DJ
04/17ACREAGE : Canopy Growth nearing deal to buy U.S.-based pot company Acreage Holdi..
RE
04/17MERCK AND : on Pace for Largest Percent Decrease in Over a Year -- Data Talk
DJ
More sector news : Pharmaceuticals - NEC
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Average target price 16,4  GBP
Spread / Average Target 7,3%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Paul Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE2.23%98 796
JOHNSON & JOHNSON6.56%366 184
ROCHE HOLDING LTD.8.22%224 445
PFIZER-9.78%218 630
NOVARTIS3.69%194 472
MERCK AND COMPANY-4.21%189 055